A rapid and sustained improvement of calcification propensity score (serum T-50) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate

作者：Smerud Knut T^*; A**erg Anders; Kile Hakon; Pasch Andreas; Dahle Dag O; Bollerslev Jens; Godang Kristin; Hartmann Anders

来源：Clinical Transplantation, 2017, 31(12): e13131.

DOI：10.1111/ctr.13131

• 1-year longitudinal randomized placebo-controlled clinical trial
• calcification propensity score T-50
• ibandronate
• kidney transplantation

A serum test called T-50 assesses the overall propensity for calcification of the blood and is associated with cardiovascular outcomes. We aimed to examine T-50 over time in kidney transplant recipients and also address any effects of ibandronate. Serum samples taken from kidney transplant patients included in a prospective, randomized placebo controlled study of ibandronate were analyzed in retrospect. Adequate analyses were performed at baseline (approximately 3weeks after transplantation) in 129 patients, at 10weeks in 127 patients and at 1year in 123 patients. There were no statistical differences between ibandronate and placebo treatment in terms of T-50 at 10weeks (P=.094) or at 1year (P=.116). Baseline T-50 was a significant covariate (P<.0001) for T-50 scores at 10weeks and 1year. In the total cohort, there was a highly significant (P<.0001) increase in T-50 of 26.6% after 10weeks and T-50 remained stable after 1year. T-50 change was inversely correlated to phosphate of -0.515 (P<.0001) and to change in serum albumin (P<.03). We found that T-50 increased from baseline to 10weeks after transplantation with no further change after 1year. Ibandronate had no effect on T-50.

• 出版日期2017-12